Key result
TGF-beta 1 at 15 ng/ml for 24 hours inhibited bFGF-induced DNA synthesis in cardiac fibroblasts, coinciding with phenotypic modulation and the expression of sarcomeric actin mRNA.
Why the study?
Does TGF-beta 1 regulate the proliferative capacity and phenotypic modulation of cardiac fibroblasts?
Does TGF-beta 1 regulate the proliferative capacity and phenotypic modulation of cardiac fibroblasts?
TGF-beta 1 regulates the proliferative capacity and phenotypic modulation of cardiac fibroblasts in vitro, suggesting a role in cardiac remodeling.
Answers are grounded in this paper and cite their sources.
In vitro data link TGF-beta 1 to fibroblast modulation; leaves open its role in human cardiac remodeling.
Cardiac fibroblasts constitute greater than 90% of the non-myocyte cells in the heart. Previously, it was established that cardiac fibroblasts are predisposed to transformation into a phenotype with muscle-specific features and that transforming growth factor-beta 1 (TGF-beta 1) is a specific inducer of this event. In this study the hypothesis that TGF-beta 1-induced phenotypic modulation of cardiac fibroblasts is associated with their altered proliferative capacity is tested. Therefore the effects of TGF-beta 1 on DNA synthesis in cardiac fibroblasts under normal conditions of cell culture and in response to a potent mitogen, basic fibroblasts growth factor (bFGF) were determined. The results showed that TGF-beta 1 at 15 ng/ml (a concentration that induces fibroblast "transformation") had a regulatory effect on proliferative capacity of cardiac fibroblasts which varied as the function of cell density in culture. In subconfluent and confluent cultures, pre-treatment of cardiac fibroblasts with TGF-beta 1 for 24 h resulted in a dramatic shift in the bFGF-induced stimulation of DNA synthesis. TGF-beta 1-induced inhibition of DNA synthesis in cardiac fibroblasts coincided with their phenotypic modulation as evidenced by the expression of sarcomeric actin mRNA and morphological changes. Cross-linking studies with [125I]-labeled TGF-beta 1 showed the presence of conventional types I, II and III TGF-beta 1 receptor complexes on cardiac fibroblasts and their binding to TGF-beta 1 under the experimental conditions. In summary, these data indicate that the proliferative capacity of cardiac fibroblasts is controlled by TGF-beta 1. They further suggest that the TGF-beta 1-induced phenotypic modulation of cardiac fibroblasts may be extended to include their altered proliferative capacity.
No takes yet. Share an insight, caveat, or question.
Sigel et al. (1996) studied In vitro cardiac fibroblasts. Transforming growth factor-beta 1 (TGF-beta 1) vs. Normal conditions / bFGF alone was evaluated on DNA synthesis. TGF-beta 1 at 15 ng/ml for 24 hours inhibited bFGF-induced DNA synthesis in cardiac fibroblasts, coinciding with phenotypic modulation and the expression of sarcomeric actin mRNA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: